A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma()

A deepened understanding of the cellular and molecular processes in the tumor microenvironment is necessary for the development of precision immunotherapy (IT). We simultaneously investigated CD3, PDL1, and IDO by immunohistochemistry in paired biopsies from various organs of 43 metastatic melanoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Krähenbühl, Lukas, Goldinger, Simone M, Mangana, Joanna, Kerl, Katrin, Chevolet, Ines, Brochez, Liève, Horak, Christine, Levesque, Mitch, Dummer, Reinhard, Cheng, Phil F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2018
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5767907/
https://www.ncbi.nlm.nih.gov/pubmed/29331888
http://dx.doi.org/10.1016/j.neo.2017.12.002
_version_ 1783292612531191808
author Krähenbühl, Lukas
Goldinger, Simone M
Mangana, Joanna
Kerl, Katrin
Chevolet, Ines
Brochez, Liève
Horak, Christine
Levesque, Mitch
Dummer, Reinhard
Cheng, Phil F
author_facet Krähenbühl, Lukas
Goldinger, Simone M
Mangana, Joanna
Kerl, Katrin
Chevolet, Ines
Brochez, Liève
Horak, Christine
Levesque, Mitch
Dummer, Reinhard
Cheng, Phil F
author_sort Krähenbühl, Lukas
collection PubMed
description A deepened understanding of the cellular and molecular processes in the tumor microenvironment is necessary for the development of precision immunotherapy (IT). We simultaneously investigated CD3, PDL1, and IDO by immunohistochemistry in paired biopsies from various organs of 43 metastatic melanoma patients treated with IT and targeted therapy (TT). Intraindividual biopsies taken after a period of weeks to months demonstrate discordant results in 30% of the cases. Overlap of IDO and PDL1 increased after therapy. IT only marginally impacted PDL1 expression over time in contrast to TT. Standardized repeated assessments of multiple immune markers in repeated biopsies will generate detailed insights in melanoma's immune evolution and adaption during therapies and might be used to support treatment decisions.
format Online
Article
Text
id pubmed-5767907
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Neoplasia Press
record_format MEDLINE/PubMed
spelling pubmed-57679072018-01-18 A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma() Krähenbühl, Lukas Goldinger, Simone M Mangana, Joanna Kerl, Katrin Chevolet, Ines Brochez, Liève Horak, Christine Levesque, Mitch Dummer, Reinhard Cheng, Phil F Neoplasia Original article A deepened understanding of the cellular and molecular processes in the tumor microenvironment is necessary for the development of precision immunotherapy (IT). We simultaneously investigated CD3, PDL1, and IDO by immunohistochemistry in paired biopsies from various organs of 43 metastatic melanoma patients treated with IT and targeted therapy (TT). Intraindividual biopsies taken after a period of weeks to months demonstrate discordant results in 30% of the cases. Overlap of IDO and PDL1 increased after therapy. IT only marginally impacted PDL1 expression over time in contrast to TT. Standardized repeated assessments of multiple immune markers in repeated biopsies will generate detailed insights in melanoma's immune evolution and adaption during therapies and might be used to support treatment decisions. Neoplasia Press 2018-01-12 /pmc/articles/PMC5767907/ /pubmed/29331888 http://dx.doi.org/10.1016/j.neo.2017.12.002 Text en © 2018 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original article
Krähenbühl, Lukas
Goldinger, Simone M
Mangana, Joanna
Kerl, Katrin
Chevolet, Ines
Brochez, Liève
Horak, Christine
Levesque, Mitch
Dummer, Reinhard
Cheng, Phil F
A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma()
title A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma()
title_full A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma()
title_fullStr A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma()
title_full_unstemmed A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma()
title_short A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma()
title_sort longitudinal analysis of ido and pdl1 expression during immune- or targeted therapy in advanced melanoma()
topic Original article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5767907/
https://www.ncbi.nlm.nih.gov/pubmed/29331888
http://dx.doi.org/10.1016/j.neo.2017.12.002
work_keys_str_mv AT krahenbuhllukas alongitudinalanalysisofidoandpdl1expressionduringimmuneortargetedtherapyinadvancedmelanoma
AT goldingersimonem alongitudinalanalysisofidoandpdl1expressionduringimmuneortargetedtherapyinadvancedmelanoma
AT manganajoanna alongitudinalanalysisofidoandpdl1expressionduringimmuneortargetedtherapyinadvancedmelanoma
AT kerlkatrin alongitudinalanalysisofidoandpdl1expressionduringimmuneortargetedtherapyinadvancedmelanoma
AT chevoletines alongitudinalanalysisofidoandpdl1expressionduringimmuneortargetedtherapyinadvancedmelanoma
AT brochezlieve alongitudinalanalysisofidoandpdl1expressionduringimmuneortargetedtherapyinadvancedmelanoma
AT horakchristine alongitudinalanalysisofidoandpdl1expressionduringimmuneortargetedtherapyinadvancedmelanoma
AT levesquemitch alongitudinalanalysisofidoandpdl1expressionduringimmuneortargetedtherapyinadvancedmelanoma
AT dummerreinhard alongitudinalanalysisofidoandpdl1expressionduringimmuneortargetedtherapyinadvancedmelanoma
AT chengphilf alongitudinalanalysisofidoandpdl1expressionduringimmuneortargetedtherapyinadvancedmelanoma
AT krahenbuhllukas longitudinalanalysisofidoandpdl1expressionduringimmuneortargetedtherapyinadvancedmelanoma
AT goldingersimonem longitudinalanalysisofidoandpdl1expressionduringimmuneortargetedtherapyinadvancedmelanoma
AT manganajoanna longitudinalanalysisofidoandpdl1expressionduringimmuneortargetedtherapyinadvancedmelanoma
AT kerlkatrin longitudinalanalysisofidoandpdl1expressionduringimmuneortargetedtherapyinadvancedmelanoma
AT chevoletines longitudinalanalysisofidoandpdl1expressionduringimmuneortargetedtherapyinadvancedmelanoma
AT brochezlieve longitudinalanalysisofidoandpdl1expressionduringimmuneortargetedtherapyinadvancedmelanoma
AT horakchristine longitudinalanalysisofidoandpdl1expressionduringimmuneortargetedtherapyinadvancedmelanoma
AT levesquemitch longitudinalanalysisofidoandpdl1expressionduringimmuneortargetedtherapyinadvancedmelanoma
AT dummerreinhard longitudinalanalysisofidoandpdl1expressionduringimmuneortargetedtherapyinadvancedmelanoma
AT chengphilf longitudinalanalysisofidoandpdl1expressionduringimmuneortargetedtherapyinadvancedmelanoma

Ejemplares similares